Pub Date : 2020-11-24DOI: 10.15406/jlprr.2020.07.00236
R. Jamshidi, K. Hajizadeh
Regarding the fact that cell shape indicates cell health and is of particular importance in the evaluation of new therapies, in this study, stem cell deformation during Atmospheric Pressure Plasma (APP) treatment was investigated. Given that, cell deformation is a warning of cell damage, it is therefore expected that APP-based therapy, a new modern technology that is expanding worldwide, will not lead to the deformation of normal cells. Here, the stem cells exposed to Helium-fed jet plasma, with two di erent powers of 15 and 25W. Moreover, the duration of exposure was changed (30, 50, 70, and 90 seconds) to determine the most appropriate exposure time and voltage, which maintains stem cells’ health condition. First of all, it was found that cold plasma at low power does not change the shape and elongation of stem cells. Besides, it was found that if the power of a cold plasma source is 25W, it will raise cell growth rate. In this paper, the gas ow rate of the helium plasma jet was set to 3.9 liters per minute, and a plasma source frequency of 30kHz was selected.
{"title":"Cold atmospheric plasma risk assessment: stem cells","authors":"R. Jamshidi, K. Hajizadeh","doi":"10.15406/jlprr.2020.07.00236","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00236","url":null,"abstract":"Regarding the fact that cell shape indicates cell health and is of particular importance in the evaluation of new therapies, in this study, stem cell deformation during Atmospheric Pressure Plasma (APP) treatment was investigated. Given that, cell deformation is a warning of cell damage, it is therefore expected that APP-based therapy, a new modern technology that is expanding worldwide, will not lead to the deformation of normal cells. Here, the stem cells exposed to Helium-fed jet plasma, with two di erent powers of 15 and 25W. Moreover, the duration of exposure was changed (30, 50, 70, and 90 seconds) to determine the most appropriate exposure time and voltage, which maintains stem cells’ health condition. First of all, it was found that cold plasma at low power does not change the shape and elongation of stem cells. Besides, it was found that if the power of a cold plasma source is 25W, it will raise cell growth rate. In this paper, the gas ow rate of the helium plasma jet was set to 3.9 liters per minute, and a plasma source frequency of 30kHz was selected.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86262036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-17DOI: 10.15406/jlprr.2020.07.00235
R. P. Thiruvenkataramani, A. Abdul-Hafez, I. Gewolb, B. Uhal
Background: Hyperoxia in pre-term neonates is a known risk factor of bronchopulmonary dysplasia (BPD). Hyperoxia is known to cause oxidative stress, inflammatory changes that leads to surfactant deactivation, and decreased surfactant expression. The previous research has shown short term exposure to hyperoxia increases surfactant protein expression but decreased expression in long term exposure. Local tissue renin-angiotensin system (RAS) is associated with tissue injury and repair and it may play a role in BPD. Endogenous peptide angiotensin 1–7 acts on the MAS receptor. The activation of the MAS receptor was previously shown to have protective pulmonary responses. However, the effect of MAS receptor activation on surfactant proteins in hyperoxic conditions has not been tested. Objective: To determine the effects of hyperoxia with or without MAS receptor activation on Surfactant proteins. Methods: Human epithelial cell line A549 and human primary alveolar epithelial cells (AECs) were cultured to sub-confluence (60–75%) and treated with hyperoxia (95% oxygen) and normoxia (21% oxygen) for 72 hours with or without the MAS receptor agonist (AVE0991) in serum-free F-12 nutrient media. Cells were lysed and cell lysates were collected for western blot. The statistical analysis was done using Student-Newman-Keuls Multiple comparison test. Results: Surfactant protein concentration increased in AVE treated group under the hyperoxic condition when compared to the control group in both A549 cells and human primary AECs. Surfactant protein was in higher concentration in AVE0991 treated cells in both hyperoxic and normoxic conditions when compared to the non-treated control group. Conclusions: MAS receptor activation via AVE0991 causes an increase in Surfactant protein concentration in both hyperoxic and normoxic conditions. As per our experiments, hyperoxic conditions decrease the production of surfactant protein when compared to normoxic conditions. These results may reveal a novel potential drug for BPD treatment and decrease its severity.
{"title":"Mas Receptor Agonist AVE0991 increases surfactant protein expression under hyperoxic conditions in human lung epithelial cells","authors":"R. P. Thiruvenkataramani, A. Abdul-Hafez, I. Gewolb, B. Uhal","doi":"10.15406/jlprr.2020.07.00235","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00235","url":null,"abstract":"Background: Hyperoxia in pre-term neonates is a known risk factor of bronchopulmonary dysplasia (BPD). Hyperoxia is known to cause oxidative stress, inflammatory changes that leads to surfactant deactivation, and decreased surfactant expression. The previous research has shown short term exposure to hyperoxia increases surfactant protein expression but decreased expression in long term exposure. Local tissue renin-angiotensin system (RAS) is associated with tissue injury and repair and it may play a role in BPD. Endogenous peptide angiotensin 1–7 acts on the MAS receptor. The activation of the MAS receptor was previously shown to have protective pulmonary responses. However, the effect of MAS receptor activation on surfactant proteins in hyperoxic conditions has not been tested. Objective: To determine the effects of hyperoxia with or without MAS receptor activation on Surfactant proteins. Methods: Human epithelial cell line A549 and human primary alveolar epithelial cells (AECs) were cultured to sub-confluence (60–75%) and treated with hyperoxia (95% oxygen) and normoxia (21% oxygen) for 72 hours with or without the MAS receptor agonist (AVE0991) in serum-free F-12 nutrient media. Cells were lysed and cell lysates were collected for western blot. The statistical analysis was done using Student-Newman-Keuls Multiple comparison test. Results: Surfactant protein concentration increased in AVE treated group under the hyperoxic condition when compared to the control group in both A549 cells and human primary AECs. Surfactant protein was in higher concentration in AVE0991 treated cells in both hyperoxic and normoxic conditions when compared to the non-treated control group. Conclusions: MAS receptor activation via AVE0991 causes an increase in Surfactant protein concentration in both hyperoxic and normoxic conditions. As per our experiments, hyperoxic conditions decrease the production of surfactant protein when compared to normoxic conditions. These results may reveal a novel potential drug for BPD treatment and decrease its severity.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"1 1","pages":"85 - 91"},"PeriodicalIF":0.0,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86499851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-04DOI: 10.15406/jlprr.2020.07.00234
A. Cheepsattayakorn, R. Cheepsattayakorn
Currently, animal-to-human transmission of SARS-CoV-2 (COVID-19) has not yet been confirmed, whereas the main mode of transmission is human-to-human. Droplets are the main route of human-to-human transmission, whereas aerosols could be another route in addition to stool-based transmission. Currently, no evidence is available to indicate intrauterine vertical transmission of SARS-CoV-2 (COVID-19) in pregnant women. In the host, the life cycle of coronavirus consists of 5 steps: 1) attachment, 2) penetration, 3) biosynthesis, 4) maturation, and 5) release. Once viruses bind to host receptors (attachment), they enter host cells, particularly type II pneumocytes via endocytosis or membrane fusion (penetration). Once viral contents are released inside the host cells, viral RNA enters the host’s nucleus for replication and making viral proteins (biosynthesis). New viral particles are produced (maturation) and released. Spike protein of coronaviruses which determines the diversity of coronaviruses and host tropism is composed of a transmembrane trimetric glycoprotein protruding from the viral surface. Structural and functional studies demonstrated that the spike protein the of coronaviruses can bind to angiotensin converting enzyme 2 (ACE2), a functional receptor for SARS-CoV. ACE2 expression is high in lung (high expression on lung epithelial cells), heart, ileum, and kidney. The lungs of severe COVID-19 patients demonstrate infiltration of a large number of inflammatory cells. Due to high ACE2 expression on the apical side of lung epithelial cells in the alveolar space, SARS-CoV-2 (COVID-19) can enter and destroy lung epithelial cells. Significant ACE2 expression on innate lymphoid cells (ILC)2, ILC3, and endothelial cells is also demonstrated. Pulmonary endothelial cells represent one third of the lung cells. Endothelial function includes promotion of anti-aggregation, fibrinolysis, and vasodilatation. Due to a significant role playing in thrombotic regulation, hypercoagulable profiles that are demonstrated in severe COVID-19 patients likely suggest significant endothelial injury. Pulmonary thrombosis and embolism accompanying elevation of d-dimer and fibrinogen levels have been demonstrated in severe COVID-19. In conclusion, whether these histopathological lesions are direct consequences of sepsis, SARS-CoV-2 (C)OVID-19), and /or multiple organ failure is difficult to conclude. Further studies on understanding the roles of ILC1, ILC2, ILC3, including the difference in response to SARS-CoV-2 (COVID-19) infection between children and adults are urgently needed to develop efficient targeted therapies.
{"title":"Pulmonary pathology of COVID-19","authors":"A. Cheepsattayakorn, R. Cheepsattayakorn","doi":"10.15406/jlprr.2020.07.00234","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00234","url":null,"abstract":"Currently, animal-to-human transmission of SARS-CoV-2 (COVID-19) has not yet been confirmed, whereas the main mode of transmission is human-to-human. Droplets are the main route of human-to-human transmission, whereas aerosols could be another route in addition to stool-based transmission. Currently, no evidence is available to indicate intrauterine vertical transmission of SARS-CoV-2 (COVID-19) in pregnant women. In the host, the life cycle of coronavirus consists of 5 steps: 1) attachment, 2) penetration, 3) biosynthesis, 4) maturation, and 5) release. Once viruses bind to host receptors (attachment), they enter host cells, particularly type II pneumocytes via endocytosis or membrane fusion (penetration). Once viral contents are released inside the host cells, viral RNA enters the host’s nucleus for replication and making viral proteins (biosynthesis). New viral particles are produced (maturation) and released. Spike protein of coronaviruses which determines the diversity of coronaviruses and host tropism is composed of a transmembrane trimetric glycoprotein protruding from the viral surface. Structural and functional studies demonstrated that the spike protein the of coronaviruses can bind to angiotensin converting enzyme 2 (ACE2), a functional receptor for SARS-CoV. ACE2 expression is high in lung (high expression on lung epithelial cells), heart, ileum, and kidney. The lungs of severe COVID-19 patients demonstrate infiltration of a large number of inflammatory cells. Due to high ACE2 expression on the apical side of lung epithelial cells in the alveolar space, SARS-CoV-2 (COVID-19) can enter and destroy lung epithelial cells. Significant ACE2 expression on innate lymphoid cells (ILC)2, ILC3, and endothelial cells is also demonstrated. Pulmonary endothelial cells represent one third of the lung cells. Endothelial function includes promotion of anti-aggregation, fibrinolysis, and vasodilatation. Due to a significant role playing in thrombotic regulation, hypercoagulable profiles that are demonstrated in severe COVID-19 patients likely suggest significant endothelial injury. Pulmonary thrombosis and embolism accompanying elevation of d-dimer and fibrinogen levels have been demonstrated in severe COVID-19. In conclusion, whether these histopathological lesions are direct consequences of sepsis, SARS-CoV-2 (C)OVID-19), and /or multiple organ failure is difficult to conclude. Further studies on understanding the roles of ILC1, ILC2, ILC3, including the difference in response to SARS-CoV-2 (COVID-19) infection between children and adults are urgently needed to develop efficient targeted therapies.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73160765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-15DOI: 10.15406/jlprr.2020.07.00233
Mohammed H Saiem Al-Dahr
Background: Asthma is a chronic conducting airway disorder which characterized by reversible airway inflammation and obstruction. However, prevalence of some pulmonary disorders as bronchial asthma is increased with Vitamin D deficiency. Objective: The target of this study is to evaluate the association between status of vitamin D and ventilatory function & asthma control in patients with bronchial asthma in Jeddah area. Material and methods: One hundred Saudi patients with asthma of both sex; their age mean was 35.18±6.27 year were selected on referral to Internal Medicine Department, King Abdulaziz University Teaching Hospital, Saudi Arabia. Asthma was diagnosed by spirometry tests. Criteria for asthma diagnosis were in accordance with the Global Strategy for Asthma Management and Prevention (GINA 2016). Exclusion criteria included patients with renal, cardiac and liver diseases. All participants will be free to withdraw from the study at any time. Following pre-training testing, participants were enrolled in three groups according to 25-OHD levels: vitamin D deficiency group (A) 25-OHD level <20ng/ml, vitamin D deficiency group (B) 25-OHD level=20–30 ng/ml and normal vitamin D group(C) 25-OHD level >30ng/ml. Results: There was significant higher values of FVC, FEV1 and FEV1/FVC in group (C) compared to subgroup (A) and group (B) in addition to lower values of asthma control test in subgroup (C) compared to group (A) and group (B). While there was significant difference between groups. Moreover, the 25-OHD showed a strong direct relationship with FVC, FEV1, FEV1/FVC and asthma control test in the three groups (P<0.05). Conclusion: There is a close direct relationship between level of vitamin D, ventilatory function and asthma control in patients with bronchial asthma.
{"title":"Vitamin D, ventilatory function and asthma control among bronchial asthma patients","authors":"Mohammed H Saiem Al-Dahr","doi":"10.15406/jlprr.2020.07.00233","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00233","url":null,"abstract":"Background: Asthma is a chronic conducting airway disorder which characterized by reversible airway inflammation and obstruction. However, prevalence of some pulmonary disorders as bronchial asthma is increased with Vitamin D deficiency. Objective: The target of this study is to evaluate the association between status of vitamin D and ventilatory function & asthma control in patients with bronchial asthma in Jeddah area. Material and methods: One hundred Saudi patients with asthma of both sex; their age mean was 35.18±6.27 year were selected on referral to Internal Medicine Department, King Abdulaziz University Teaching Hospital, Saudi Arabia. Asthma was diagnosed by spirometry tests. Criteria for asthma diagnosis were in accordance with the Global Strategy for Asthma Management and Prevention (GINA 2016). Exclusion criteria included patients with renal, cardiac and liver diseases. All participants will be free to withdraw from the study at any time. Following pre-training testing, participants were enrolled in three groups according to 25-OHD levels: vitamin D deficiency group (A) 25-OHD level <20ng/ml, vitamin D deficiency group (B) 25-OHD level=20–30 ng/ml and normal vitamin D group(C) 25-OHD level >30ng/ml. Results: There was significant higher values of FVC, FEV1 and FEV1/FVC in group (C) compared to subgroup (A) and group (B) in addition to lower values of asthma control test in subgroup (C) compared to group (A) and group (B). While there was significant difference between groups. Moreover, the 25-OHD showed a strong direct relationship with FVC, FEV1, FEV1/FVC and asthma control test in the three groups (P<0.05). Conclusion: There is a close direct relationship between level of vitamin D, ventilatory function and asthma control in patients with bronchial asthma.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75264818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-14DOI: 10.15406/jlprr.2020.07.00232
S. Thomas, H. Patel
A 41-year-old patient with Metastatic Breast Cancer suffered from pneumonitis after administration of cyclophosphamide. A CT angiogram with IV contrast was compatible with bronchopneumonia and it was treated with broad spectrum antibiotics. Other causes of pulmonary disease were ruled out concluding patient developed cyclophosphamide induced pneumonitis. Thus, more attention is required to the serious and rare side effects of cyclophosphamide related lung toxicities. In this case report, we will focus on the rare side effects such as cyclophosphamide-induced pneumonitis (AIP) occurring in less than 1% of the population.
{"title":"A rare side effect of Cyclophosphamide Induced Acute Interstitial Pneumonitis: a case report","authors":"S. Thomas, H. Patel","doi":"10.15406/jlprr.2020.07.00232","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00232","url":null,"abstract":"A 41-year-old patient with Metastatic Breast Cancer suffered from pneumonitis after administration of cyclophosphamide. A CT angiogram with IV contrast was compatible with bronchopneumonia and it was treated with broad spectrum antibiotics. Other causes of pulmonary disease were ruled out concluding patient developed cyclophosphamide induced pneumonitis. Thus, more attention is required to the serious and rare side effects of cyclophosphamide related lung toxicities. In this case report, we will focus on the rare side effects such as cyclophosphamide-induced pneumonitis (AIP) occurring in less than 1% of the population.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"207 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78123054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-28DOI: 10.15406/jlprr.2020.07.00231
E. Dias, J. Caldeira, Margarida Pimenta Queiroz Valério, Ana Maria da Fonseca Arrobas Correia de Matos
followed fluticasone propionate (n=2, 28.6%). One is on high dose budesonide (>800 µg/day), 1 medium dose budesonide (> 400-800µg/day), 3 low dose budesonide (200-400 µg/ day), 1 high dose fluticasone (>500µg/day) and 1 patient low dose fluticasone (100-250µg/day). Inhaled corticosteroids (ICS) are widely used in the treatment of asthma but their safety on bone density is controversial. 1 Bone mineral density (BMD) is assessed by DEXA - dual energy radiologic absorptiometry (osteodensitometry) - performed at the proximal femur and lumbar spine levels. The absolute BMD values and the T-score (femoral neck, total hip and lumbar spine) should be taken into account in postmenopausal women and in men over 50 years of age (T-score≥-1:normal; -2.5
{"title":"Inhaled corticosteroid therapy in Asthma and Osteoporosis","authors":"E. Dias, J. Caldeira, Margarida Pimenta Queiroz Valério, Ana Maria da Fonseca Arrobas Correia de Matos","doi":"10.15406/jlprr.2020.07.00231","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00231","url":null,"abstract":"followed fluticasone propionate (n=2, 28.6%). One is on high dose budesonide (>800 µg/day), 1 medium dose budesonide (> 400-800µg/day), 3 low dose budesonide (200-400 µg/ day), 1 high dose fluticasone (>500µg/day) and 1 patient low dose fluticasone (100-250µg/day). Inhaled corticosteroids (ICS) are widely used in the treatment of asthma but their safety on bone density is controversial. 1 Bone mineral density (BMD) is assessed by DEXA - dual energy radiologic absorptiometry (osteodensitometry) - performed at the proximal femur and lumbar spine levels. The absolute BMD values and the T-score (femoral neck, total hip and lumbar spine) should be taken into account in postmenopausal women and in men over 50 years of age (T-score≥-1:normal; -2.5<T-score<-1:osteopenia; T-score≤-2.5:osteoporosis). In premenopausal","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90033873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-18DOI: 10.15406/jlprr.2020.07.00229
Toshiro Takami
The patient complained of nasal odor and was referred to a psychiatrist by the Department of Otolaryngology as a case of olfactory reference syndrome. The patient had a strong nasal odor. The doctor denied the existence of atrophic rhinitis and rhinophobia. If you look around the internet, there are many who suffer from similar conditions. Almost all of them complain of an unusually dry nose. It was thought that Pseudomonas aeruginosa or some fungus grew abnormally in the devastated nasal mucosa of the endogenous nasal cavity, and due to inadequate nasal secretion, the bacterial metabolites could not be forced down the throat or other parts of the body, giving off a strong nasal odor. This disorder is often neglected or diagnosed by psychiatrists as olfactory reference syndrome. The term "nasal secretion insufficiency syndrome" is used to describe this condition. This is a new concept of nasal odor disease, which remains unnoticed, partly because there is no crusting or atrophy of the native nasal cavity, and partly because endoscopy reveals only the devastation of the nasal mucosa, and partly because it is hidden behind the veil of atrophic rhinitis and ozena. In all seven cases, the foul odor is weakened, albeit temporarily, by the use of saliva-enhancing drugs.
{"title":"Nasal secretion insufficiency syndrome (new concept of ozena)","authors":"Toshiro Takami","doi":"10.15406/jlprr.2020.07.00229","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00229","url":null,"abstract":"The patient complained of nasal odor and was referred to a psychiatrist by the Department of Otolaryngology as a case of olfactory reference syndrome. The patient had a strong nasal odor. The doctor denied the existence of atrophic rhinitis and rhinophobia. If you look around the internet, there are many who suffer from similar conditions. Almost all of them complain of an unusually dry nose. It was thought that Pseudomonas aeruginosa or some fungus grew abnormally in the devastated nasal mucosa of the endogenous nasal cavity, and due to inadequate nasal secretion, the bacterial metabolites could not be forced down the throat or other parts of the body, giving off a strong nasal odor. This disorder is often neglected or diagnosed by psychiatrists as olfactory reference syndrome. The term \"nasal secretion insufficiency syndrome\" is used to describe this condition. This is a new concept of nasal odor disease, which remains unnoticed, partly because there is no crusting or atrophy of the native nasal cavity, and partly because endoscopy reveals only the devastation of the nasal mucosa, and partly because it is hidden behind the veil of atrophic rhinitis and ozena. In all seven cases, the foul odor is weakened, albeit temporarily, by the use of saliva-enhancing drugs.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89403839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-16DOI: 10.15406/jlprr.2020.07.00228
Tarig Fadelelmoula
The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.
{"title":"Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols","authors":"Tarig Fadelelmoula","doi":"10.15406/jlprr.2020.07.00228","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00228","url":null,"abstract":"The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85020146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-14DOI: 10.15406/jlprr.2020.07.00227
W. Tangsawad
Background: The purpose of this study was to evaluate the result of the multilevel single-stage procedure for obstructive sleep apnea (OSA) with a narrow nasal cavity and oropharyngeal, velopharyngeal airspace. A retrospective study was performed in OSA patients who underwent surgery in Khon Kaen hospital, Thailand. Methods: A retrospective study was conducted and medical records were reviewed between 2015 May and 2019 November in patients with loud snoring and having symptoms and signs of OSA, 43 patients included for evaluation history taking and physical examination by fiberoptic laryngoscope and performed multilevel single-stage procedure and evaluated clinical postoperative. Results: All patients were evaluated preoperatively by a history taking and physical examination for clinical assessment including fiberoptic laryngoscope examination. There were 3 surgical procedure, Procedure 1: 12 patients underwent Tonsillectomy with uvulopalatopharyngoplasty (27.9%), Procedure 2: 22 patients underwent Tonsillectomy with uvulopalatopharyngoplasty and inferior turbinoplasty (51.2%), Procedure 3: 9 patients underwent Tonsillectomy with uvulopalatopharyngoplasty and inferior turbinoplasty, and septoplasty (20.9%). After a 1-week post-operation 41 patients (95.3%), all (100.0%) no symptoms of OSA, and 60.9% improved their loud snoring more than 80.0%. After 3-week post-operation, 32 patients (74.4%) followed up and all (100.0%) no symptoms of OSA, 27 patients (84.4%) improved their loud snoring by more than 80.0%. Conclusion: Clinical assessment in patient with OSA is important before treatment. The Multilevel single-stage procedure is alternative choice for first treatment of OSA patients who reject continuous positive airway pressure (CPAP) or failure using CPAP. The results outcome is good for both obesity and non-obesity patients and improve clinical in OSA.
{"title":"Surgical treatment outcome of obstructive sleep apnea patient with nasal cavity and oropharyngeal airway abnormality","authors":"W. Tangsawad","doi":"10.15406/jlprr.2020.07.00227","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00227","url":null,"abstract":"Background: The purpose of this study was to evaluate the result of the multilevel single-stage procedure for obstructive sleep apnea (OSA) with a narrow nasal cavity and oropharyngeal, velopharyngeal airspace. A retrospective study was performed in OSA patients who underwent surgery in Khon Kaen hospital, Thailand. Methods: A retrospective study was conducted and medical records were reviewed between 2015 May and 2019 November in patients with loud snoring and having symptoms and signs of OSA, 43 patients included for evaluation history taking and physical examination by fiberoptic laryngoscope and performed multilevel single-stage procedure and evaluated clinical postoperative. Results: All patients were evaluated preoperatively by a history taking and physical examination for clinical assessment including fiberoptic laryngoscope examination. There were 3 surgical procedure, Procedure 1: 12 patients underwent Tonsillectomy with uvulopalatopharyngoplasty (27.9%), Procedure 2: 22 patients underwent Tonsillectomy with uvulopalatopharyngoplasty and inferior turbinoplasty (51.2%), Procedure 3: 9 patients underwent Tonsillectomy with uvulopalatopharyngoplasty and inferior turbinoplasty, and septoplasty (20.9%). After a 1-week post-operation 41 patients (95.3%), all (100.0%) no symptoms of OSA, and 60.9% improved their loud snoring more than 80.0%. After 3-week post-operation, 32 patients (74.4%) followed up and all (100.0%) no symptoms of OSA, 27 patients (84.4%) improved their loud snoring by more than 80.0%. Conclusion: Clinical assessment in patient with OSA is important before treatment. The Multilevel single-stage procedure is alternative choice for first treatment of OSA patients who reject continuous positive airway pressure (CPAP) or failure using CPAP. The results outcome is good for both obesity and non-obesity patients and improve clinical in OSA.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86558345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-02DOI: 10.15406/jlprr.2020.07.00225
N. Syabbalo
Asthma is a common chronic airway disease affecting about 334 million people worldwide, and up to 10% of asthma patients have severe asthma, which may be uncontrolled despite high doses of the standard treatment modifiers and may require the use of chronic oral corticosteroids. It is the most common chronic disease in children in the developed countries. Asthmamanifests as reversible airflow obstruction, due to airway inflammation, bronchial smooth muscle contraction, increased mucus secretion, vascular engorgement, mucosal oedema, and airway hyper responsiveness, which leads to airflow obstruction and symptoms of asthma. Eosinophilic asthma is a phenotype of asthma that is usually very severe and persistent, with frequent exacerbations. It is usually observed in adult asthmatic patients, although it may occur in children. It is characterized by the presence of high levels of eosinophils, and CD+4 Th2 cells in the lungs and airways, which can be demonstrated by a raised eosinophil count in blood, and induced sputum or bronchial biopsy. It is managed in a similar stepwise treatment for childhood-onset asthma, but some of the patients with eosinophilic asthma do not respond to this standard treatment including inhaled or oral corticosteroids. The logical approach to treat corticosteroid-refractory asthma is to target the eosinophilic interleukins which cause airway inflammation using monoclonal antibodies to block their activity on the eosinophils, and Th2 cells. Currently, the following monoclonal antibodies are used in the treatment of eosinophilic asthma: IgE antibody such as omalizumab, or interleukin receptor 5, or 4, and 13 antagonists, such mepolizumab, reslizumab, and dupilumab. These novel agents have proved to be very useful in relieving the symptoms, and in improving the forced expired volume in one second (FEV1), and in reducing exacerbations. They are also steroid-sparing agents, and improve the quality of lifein this debilitating phenotype of asthma.
{"title":"Mechanisms, diagnosis and management of eosinophilic asthma","authors":"N. Syabbalo","doi":"10.15406/jlprr.2020.07.00225","DOIUrl":"https://doi.org/10.15406/jlprr.2020.07.00225","url":null,"abstract":"Asthma is a common chronic airway disease affecting about 334 million people worldwide, and up to 10% of asthma patients have severe asthma, which may be uncontrolled despite high doses of the standard treatment modifiers and may require the use of chronic oral corticosteroids. It is the most common chronic disease in children in the developed countries. Asthmamanifests as reversible airflow obstruction, due to airway inflammation, bronchial smooth muscle contraction, increased mucus secretion, vascular engorgement, mucosal oedema, and airway hyper responsiveness, which leads to airflow obstruction and symptoms of asthma. Eosinophilic asthma is a phenotype of asthma that is usually very severe and persistent, with frequent exacerbations. It is usually observed in adult asthmatic patients, although it may occur in children. It is characterized by the presence of high levels of eosinophils, and CD+4 Th2 cells in the lungs and airways, which can be demonstrated by a raised eosinophil count in blood, and induced sputum or bronchial biopsy. It is managed in a similar stepwise treatment for childhood-onset asthma, but some of the patients with eosinophilic asthma do not respond to this standard treatment including inhaled or oral corticosteroids. The logical approach to treat corticosteroid-refractory asthma is to target the eosinophilic interleukins which cause airway inflammation using monoclonal antibodies to block their activity on the eosinophils, and Th2 cells. Currently, the following monoclonal antibodies are used in the treatment of eosinophilic asthma: IgE antibody such as omalizumab, or interleukin receptor 5, or 4, and 13 antagonists, such mepolizumab, reslizumab, and dupilumab. These novel agents have proved to be very useful in relieving the symptoms, and in improving the forced expired volume in one second (FEV1), and in reducing exacerbations. They are also steroid-sparing agents, and improve the quality of lifein this debilitating phenotype of asthma.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89142508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：